STOCK TITAN
  1. Home
  2. News
  3. AMLX

Amylyx Pharmaceuticals Inc - AMLX STOCK NEWS

Welcome to our dedicated news page for Amylyx Pharmaceuticals (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amylyx Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amylyx Pharmaceuticals's position in the market.

News
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all participants meeting responder criteria. AMX0035 was well-tolerated and demonstrated promising results, defying the typical disease progression. The trial aims to slow diabetic and visual decline in Wolfram syndrome patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.87%
Tags
clinical trial
-
News
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. announces a virtual webcast to discuss interim data from the Phase 2 trial of AMX0035 for Wolfram syndrome treatment. Dr. Fumihiko Urano to present findings on April 10, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
conferences clinical trial
-
News
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has initiated the process to discontinue the marketing authorizations for RELYVRIO/ALBRIOZA based on Phase 3 PHOENIX trial results. Patients can transition to a free drug program. The company is focusing on AMX0035 in Wolfram syndrome and PSP, and AMX0114 in ALS. A restructuring plan reduces the workforce by 70% to extend cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
News
Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) appoints Dr. Bernhardt G. Zeiher, a seasoned industry expert with over 20 years of drug development experience, to its Board of Directors. Dr. Zeiher's background includes overseeing the approval of 15 new treatments for serious diseases with unmet needs. His addition is expected to enhance Amylyx's pipeline development for neurodegenerative diseases, reinforcing the company's commitment to addressing these devastating conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.85%
Tags
management
-
News
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced topline results from the PHOENIX study, a Phase 3 clinical trial of AMX0035 in ALS, which did not meet primary or secondary endpoints. The study showed AMX0035 is safe, well-tolerated, and plans to engage with regulatory authorities and the ALS community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-82.29%
Tags
clinical trial
-
News
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. granted stock options and restricted stock units to Chief Human Resources Officer Linda Arsenault. The options allow purchasing up to 101,400 shares at $14.91 per share, with a ten-year term and four-year vesting period. RSUs will vest in four installments over four years. The grant was made under the 2023 Inducement Plan to induce Ms. Arsenault's employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
News
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) reported $380.8 million in net product revenue for full year 2023, with $108.4 million in the fourth quarter. The company achieved $49.3 million in net income for the full year, including $4.7 million in Q4. Amylyx aims to expand its presence globally with its ALS therapy, RELYVRIO, and anticipates sharing Phase 3 trial data in Q2 2024. Financially, the company ended 2023 with $371.4 million in cash, cash equivalents, and short-term investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.1%
Tags
earnings
-
News
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) will announce its Q4 and full-year 2023 financial results on February 22, 2024. The senior management team will hold a conference call to discuss the results and company updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
conferences earnings
-
News
Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced the presentation of abstracts on the development of AMX0114 for ALS treatment and findings from a study of AMX0035 at the MDA Conference. AMX0035, marketed as RELYVRIO®, is approved for ALS treatment in the U.S. and Canada. The abstracts detail the progress of AMX0114 and study results of AMX0035 in participants with ALS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
conferences
News
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has completed enrollment of its Phase 2 HELIOS trial of AMX0035 for the treatment of Wolfram syndrome, a rare genetic disease with no known cure. Preliminary results are anticipated in the second half of 2024. The trial has enrolled 12 adult participants, and the FDA has granted orphan drug designation to AMX0035 for the treatment of WS, providing potential benefits for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
clinical trial
Stock AMLX logo
Amylyx Pharmaceuticals Inc

Nasdaq:AMLX

AMLX Rankings

#4027 Ranked by Market Cap
#4813 Ranked by Stock Gains
N/A Ranked by Dividends

AMLX Stock Data

136.24M
50.94M
14.24%
104.79%
8.86%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Cambridge

About AMLX

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.